K Number
K213841
Date Cleared
2022-01-06

(28 days)

Product Code
Regulation Number
878.4810
Panel
SU
Reference & Predicate Devices
AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
Intended Use

ENEO TOTALE is an over the counter device indicated to emit energy in the red and IR region of the spectrum for use in dermatology for the treatment of periorbital wrinkles.

Device Description

ENEO TOTALE is a battery-operated device that uses low power light spectrum at red and infrared LED, at wavelength of 633 ±5nm, 830 ±5nm emitting optical power in a uniform distribution with no hot spots. It is a hand held light emitting diode(LED) device for the treatment of periorbital wrinkles designed for home-use.

AI/ML Overview

This document describes the 510(k) summary for the ENEO TOTALE device, which is indicated for the treatment of periorbital wrinkles.

1. Table of Acceptance Criteria and Reported Device Performance

The device is cleared based on demonstrating substantial equivalence to a predicate device (Avologi ENEO K181659). The "acceptance criteria" here are that the new device's specifications and performance do not raise new questions of safety or effectiveness compared to the predicate.

Feature / CriteriaPredicate Device (Avologi ENEO K181659)New Device (ENEO TOTALE)Assessment / Performance
Product CodeOHSOHSSame
Class22Same
ApplicantPremier North America IncPremier North America IncSame
Indications for UseTreatment of periorbital wrinklesTreatment of periorbital wrinklesSame
HandheldYesYesSame
Target PopulationIndividuals with periorbital lines and wrinklesIndividuals with periorbital lines and wrinklesSame
Location for UseOTCOTCSame
MaterialsABS and stainless steelABS and stainless steelSame
Visible LCDNoYesNew feature, but re-evaluated for safety/effectiveness (Note 1)
Wavelengths633 ±5nm, 830 ±5nm633 ±5nm, 830 ±5nmSame
WaveformConstantConstantSame
Light SourceLight emitting diode (LED)Light emitting diode (LED)Same
Visible Light LEDsYesYesSame
Energy Source24 LEDs (12x 633nm, 12x 830nm) over 15cm²24 LEDs (12x 633nm, 12x 830nm) over 15cm²Same
Energy Level (633nm)69mW/cm²69mW/cm²Same
Energy Level (830nm)55mW/cm²56mW/cm²Subtle difference, no new safety/effectiveness issues (Note 2)
Therapeutic Temperature Range41±2°C / 105.8±35.6°F41±2°C / 105.8±35.6°FSame
Power SupplyAdaptor: 100~240V AC 50/60Hz 2.4A; Lithium battery: 3.75Vdc, 3000 mAhAdaptor: 100~240V AC 50/60Hz 2.4A; Lithium battery: 3.75Vdc, 3000 mAhSame
Handpiece Charging MethodIn Charging cradleIn Charging cradleSame
Initial Treatment Course3 times/week for 15-20 min/session, for 1 month3 times/week for 15-20 min/session, for 1 monthSame
Maintenance RegimeOnce a week for 15-20 minutesOnce a week for 15-20 minutesSame
Anatomical SitesPeriorbital AreaPeriorbital AreaSame
Standard ComplianceIEC60601-1, IEC60601-1-2, IEC60601-1-11, IEC62471IEC60601-1, IEC60601-1-2, IEC60601-1-11, IEC62471Same
Label and LabelingMeet FDA's RequirementsMeet FDA's RequirementsSame
Software ValidationN/A (implied by predicate clearance)Tested and validated per FDA guidance for software in medical devicesNew specific testing for the LCD feature.

2. Sample Size Used for the Test Set and Data Provenance

This document does not specify human clinical trials or a specific "test set" in the context of diagnostic performance. The device is a physical therapy device. The testing conducted was non-clinical focusing on electrical safety, EMC, photobiological safety, and biocompatibility, as well as software validation. Therefore, there is no information on sample size or data provenance related to human subjects for a "test set."

3. Number of Experts Used to Establish Ground Truth for the Test Set and Their Qualifications

Not applicable. This is a non-clinical submission focused on device safety and performance criteria against engineering and biocompatibility standards, not diagnostic or treatment efficacy evaluation requiring expert ground truth on patient data.

4. Adjudication Method for the Test Set

Not applicable for the reasons stated above.

5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done

No. This document does not describe an MRMC study. The submission is for a physical device for wrinkle reduction and relies on demonstrating substantial equivalence to a predicate device through non-clinical testing.

6. If a Standalone (i.e., algorithm only without human-in-the-loop performance) Was Done

Not applicable. This device is a light therapy device, not an AI algorithm requiring standalone performance evaluation in the described context. The "software validation" mentioned refers to the proper functioning of the device's internal software, not an AI algorithm.

7. The Type of Ground Truth Used

The "ground truth" for this submission are established international consensus standards (e.g., IEC, ISO standards for electrical safety, EMC, biocompatibility) and FDA guidance for software validation. The device's performance against these standards constitutes the "ground truth" in this context.

8. The Sample Size for the Training Set

Not applicable, as this is not a submission for an AI/ML algorithm or a diagnostic device requiring a "training set" of data in that sense.

9. How the Ground Truth for the Training Set Was Established

Not applicable for the reasons stated above. The "ground truth" for the device's development and testing was based on engineering specifications and adherence to recognized safety and performance standards.

§ 878.4810 Laser surgical instrument for use in general and plastic surgery and in dermatology.

(a)
Identification. (1) A carbon dioxide laser for use in general surgery and in dermatology is a laser device intended to cut, destroy, or remove tissue by light energy emitted by carbon dioxide.(2) An argon laser for use in dermatology is a laser device intended to destroy or coagulate tissue by light energy emitted by argon.
(b)
Classification. (1) Class II.(2) Class I for special laser gas mixtures used as a lasing medium for this class of lasers. The devices subject to this paragraph (b)(2) are exempt from the premarket notification procedures in subpart E of part 807 of this chapter, subject to the limitations in § 878.9.